Alexion Pharmaceuticals Inc. (ALXN)


Stock Price Forecast

July 20, 2021


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Alexion Pharmaceuticals Inc. chart...

About the Company

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

CEO

Ludwig Hantson

Exchange

NASDAQ/NGS (GLOBAL SELECT MARKET)

Website

www.alxn.com

$6B

Total Revenue

3K

Employees

$41B

Market Capitalization

59.25

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALXN News

AstraZeneca acquires Amolyt in $1B deal

4d ago, source: usaherald

AstraZeneca, a pharmaceutical giant, announced on Thursday its acquisition of Amolyt Pharma, a clinical stage biotechnology company, in a deal valued at up to $1.05 billion. This strategic move aims ...

AstraZeneca to acquire clinical-stage biotech company, Amolyt Pharma for $1.05 billion

4d ago, source: Pharmabiz

AstraZeneca to acquire clinical-stage biotech company, Amolyt Pharma for $1.05 billion: United Kingdom Friday, March 15, 2024, 09:00 Hrs [IST] AstraZeneca has entered into a defin ...

In Connecticut’s bioscience industry, it’s still ‘early innings’ for jobs growth

7d ago, source:

Connecticut's bioscience industry has grappled with job losses in recent years, but hubs in the Hartford and New Haven areas ...

AstraZeneca adds another rare disease drug in $800M buyout of startup Amolyt

4d ago, source: BioPharma Dive

The deal gives AstraZeneca a prospect in late-stage testing for parathyroidism and bolsters a rare disease portfolio that mainly consists of drugs from Alexion.

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

16h ago, source:

WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the ...

Elliott Alumnus De La Riviere Joins Tech Entrepreneur’s Fund

6d ago, source:

Former Elliott Investment Management portfolio manager Sebastien de La Riviere is joining a new investment firm that will manage the capital of tech entrepreneur Alex Algard.

Tracking Baker Brothers Portfolio - Q4 2023 Update

12d ago, source:

Baker Brothers' 13F portfolio value has decreased from $17.35B to $8.79B. Read more to see our updated thesis of the ...

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

10d ago, source:

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...

AstraZeneca files patent for improved production of aav vectors using specific plasmid sequence

6d ago, source: Pharmaceutical Technology

Discover how AstraZeneca's new patent revolutionizes AAV vector production with specific polynucleotide sequences, excluding cap genes.

Ireland is one of slowest countries in Europe for medical reimbursment, it’s ‘a bit of a travesty for patients’

4d ago, source:

AstraZeneca’s Alex Wilkes warns Ireland needs to speed up access to medicines and expand the breadth of its pharma sector ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...